Literature DB >> 29762076

The Degeneration of the Vestibular Efferent Neurons After Intratympanic Gentamicin Administration.

Qianru Wu1, Yibo Zhang1, Chunfu Dai1, Yu Kong2, Lijun Pan2.   

Abstract

Intratympanic gentamicin (ITG) has been used to treat refractory Ménière's disease. Disequilibrium after ITG was still a challenge for some patients, and the underlying mechanism is poorly understood. Our previous study demonstrated that gentamicin distributed in the bilateral vestibular efferent neurons (VEN) after ITG; however, does it lead to VEN damage and cause further disequilibrium in patients following ITG? In this study, we observed severe damaged gentamicin-positive neurons of VEN and severe fractured myelin layer plates around neural fibers when viewed under transmission electron microscopy at day 3 after ITG. At day 30, neurons of VEN presented with relatively normal structures. Compared with the control group, the total number of choline acetyltransferase (CHAT) immunolabeling neurons in bilateral VEN showed a significant decrease both at day 3 and day 30. However, there was no significant difference in the total number of CHAT immunolabeling neurons between day 3 and day 30. It indicates that gentamicin is not only retrogradely transported into bilateral VEN, but also results in the degeneration of VEN after ITG. These findings may be related to patients' disequilibrium symptom after ITG. Furthermore, we speculate that VEN may play a role in vestibular compensation.

Entities:  

Keywords:  IHC; aminoglycoside; retrograde neuron tracing; vestibulotoxicity

Mesh:

Substances:

Year:  2018        PMID: 29762076      PMCID: PMC6213566          DOI: 10.1369/0022155418773746

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  37 in total

1.  Coexistence of acetylcholine and calcitonin gene-related peptide in the vestibular efferent neurons in the rat.

Authors:  K Ohno; N Takeda; M Yamano; T Matsunaga; M Tohyama
Journal:  Brain Res       Date:  1991-12-06       Impact factor: 3.252

2.  [Study of vestibular efferent neurons of the guinea pig by the technic of retrograde axonal transport of horseradish peroxidase and with fluorochromes].

Authors:  V F Shumilina; N N Preobrazhenskiĭ; V A Maĭskiĭ
Journal:  Neirofiziologiia       Date:  1986

3.  Identification of vestibular efferent neurons in the gerbil: histochemical and retrograde labelling.

Authors:  A A Perachio; G A Kevetter
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  Histological effects of intratympanic gentamicin on the vestibular organ of guinea pigs.

Authors:  R C Demarco; M Rossato; J A A de Oliveira; M A Hyppolito
Journal:  J Laryngol Otol       Date:  2010-11-05       Impact factor: 1.469

5.  Behavior of the vestibular nerve following labyrinthectomy.

Authors:  H F Schuknecht
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1982 Sep-Oct

6.  Survival of the vestibular nerve after labyrinthectomy in the cat.

Authors:  S P Cass; P Davidson; H Goshgarian
Journal:  Otolaryngol Head Neck Surg       Date:  1989-10       Impact factor: 3.497

7.  The distribution of vestibular efferent neurons receiving innervation of secondary vestibular afferent nerves in rats.

Authors:  Jing Wang; Fang-lu Chi; Yuan Xin; Michael F Regner
Journal:  Laryngoscope       Date:  2013-03-11       Impact factor: 3.325

8.  Vestibular nerve section versus intratympanic gentamicin for Meniere's disease.

Authors:  Todd A Hillman; Douglas A Chen; Moises A Arriaga
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

9.  Gentamicin blocks the ACh-induced BK current in guinea pig type II vestibular hair cells by competing with Ca²⁺ at the L-type calcium channel.

Authors:  Hong Yu; Chang-Kai Guo; Yi Wang; Tao Zhou; Wei-Jia Kong
Journal:  Int J Mol Sci       Date:  2014-04-22       Impact factor: 5.923

10.  Physiological characterization of vestibular efferent brainstem neurons using a transgenic mouse model.

Authors:  Sara Leijon; Anna K Magnusson
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.